Fenophibrate clinical effectiveness in oxidative stress correction for patients with diabetic neuropathy and type 2 diabetes mellitus

• Alexander S. Ametov
• Yu.A. Vladimirov
• E.V. Proskurnina
• Prudnikova M.A.

Abstract

Aims – to assess role of oxidative stress in the development of diabetic neuropathy and effectiveness of drug correction of this pathogenic factor with fenofibrate.

Methods. 50 patients with type 2 diabetes were divided into two groups: n=22 (received 145 mg of micronized fenofibrate in addition to OADs) and n=28 (no adjustment in the treatment regimen). Oxidative stress markers (TBARS, antioxidant and prooxidant activity of blood plasma), the state of the peripheral nerves (the scale of TSS and NIS-LL, electroneuromyography), plasma lipids, glucose homeostasis markers and uric acid were assessed.

Results. Prooxidant activity of blood plasma correlated with TSS scale r=0,31 (p=0.03) and the nerve conduction velocity on n. Suralis r=-0.395 (p=0.005). In the main group there was a significant reduction in prooxidant activity of blood plasma (p=0.02), TSS scale (p=0.005) and NIS-LL scale (p<0.05), significant improvement in the lipid and purine metabolism. Nerve conduction velocity n. Suralis decr eased during the monitoring period in the comparison group (р=0.004). Conclusion. micronized fenofibrate has an antioxidant effect and significantly improves the condition of the peripheral nervous system in patients with type 2 diabetes

Keywords:type 2 diabetes mellitus, diabetic neuropathy, fenofibrate, oxidative stress

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)